130 related articles for article (PubMed ID: 6890841)
1. [Influence of benzbromarone on the pharmacokinetics and pharmacodynamics of oxipurinol].
Rüffer C; Zorn G; Henkel E; Mitzkat HJ
Arzneimittelforschung; 1982; 32(9):1149-52. PubMed ID: 6890841
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.
Colin JN; Farinotti R; Fredj G; Tod M; Clavel JP; Vignon E; Dietlin F
Eur J Clin Pharmacol; 1986; 31(1):53-8. PubMed ID: 3780828
[TBL] [Abstract][Full Text] [Related]
3. [Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].
Mertz DP; Borner K
Med Welt; 1983 Sep; 34(36):974-9. PubMed ID: 6633222
[No Abstract] [Full Text] [Related]
4. Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.
Breithaupt B; Tittel M
Eur J Clin Pharmacol; 1982; 22(1):77-84. PubMed ID: 7094977
[TBL] [Abstract][Full Text] [Related]
5. Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?
Mertz DP; Eichhorn R
Klin Wochenschr; 1984 Dec; 62(24):1170-2. PubMed ID: 6530890
[TBL] [Abstract][Full Text] [Related]
6. [Clinical pharmacokinetics of allopurinol. 3. Allopurinol/oxipurinol pharmacokinetics following administration of a controlled release allopurinol preparation].
Gikalov I; Radivojevich F; Schiemann O; Fenner H
Arzneimittelforschung; 1986 Jun; 36(6):988-93. PubMed ID: 3741536
[TBL] [Abstract][Full Text] [Related]
7. [The clinical pharmacokinetics of allopurinol. 1. Allopurinol absorption sites and dose proportionality of allopurinol/oxipurinol bioavailability].
Schuster O; Haertel M; Hugemann B; Gikalov I; Schiemann O; Fenner H
Arzneimittelforschung; 1985; 35(4):760-5. PubMed ID: 4015743
[TBL] [Abstract][Full Text] [Related]
8. The effect of dietary protein on the clearance of allopurinol and oxypurinol.
Berlinger WG; Park GD; Spector R
N Engl J Med; 1985 Sep; 313(13):771-6. PubMed ID: 4033706
[TBL] [Abstract][Full Text] [Related]
9. The pharmacology of hypouricemic effect of benzbromarone.
Sinclair DS; Fox IH
J Rheumatol; 1975 Dec; 2(4):437-45. PubMed ID: 1206675
[TBL] [Abstract][Full Text] [Related]
10. [The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application].
Fenner H; Schiemann O; Gikalov I
Arzneimittelforschung; 1985; 35(7):1093-6. PubMed ID: 4052144
[TBL] [Abstract][Full Text] [Related]
11. [Time course of oxipurinol levels in plasma following single dose and chronic administration of allopurinol in different pharmaceutical preparations (author's transl)].
Walter-Sack I; Gröbner W; Zöllner N
Arzneimittelforschung; 1979; 29(5):839-42. PubMed ID: 582985
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetic interaction between the active metabolite of allopurinol and benzbromarone].
Farinotti R; Fredj G; Clavel JP; Colin JN; Nebout T
Presse Med; 1986 Mar; 15(12):579. PubMed ID: 2939409
[No Abstract] [Full Text] [Related]
13. [Uric acid-lowering effect of a combination of benzbromarone and allopurinol--studies under standardized dietary conditions].
Löffler W; Gröbner W; Zöllner N
Arzneimittelforschung; 1983; 33(12):1687-91. PubMed ID: 6686776
[TBL] [Abstract][Full Text] [Related]
14. [Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's transl)].
Mertz DP
Med Klin; 1977 Apr; 72(15):664-8. PubMed ID: 857138
[TBL] [Abstract][Full Text] [Related]
15. [Determination of benzbromarone in serum following combined therapy with allopurinol and benzbromarone (author's transl)].
Nitsche V; Mascher H
Arzneimittelforschung; 1981; 31(3):510-2. PubMed ID: 7194674
[TBL] [Abstract][Full Text] [Related]
16. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone.
Iwanaga T; Kobayashi D; Hirayama M; Maeda T; Tamai I
Drug Metab Dispos; 2005 Dec; 33(12):1791-5. PubMed ID: 16135657
[TBL] [Abstract][Full Text] [Related]
17. [The effect of benzbromarone on fasting-hyperuricemia as a model (author's transl)].
Schräpler P; Kleinschmidt A; Haese E
Med Klin; 1978 Jun; 73(23):861-6. PubMed ID: 661730
[TBL] [Abstract][Full Text] [Related]
18. [Allopurinol-benzbromarone combination. Renal excretion of various ions during high-dosage therapy using an allopurinol-benzbromarone combination].
Mertz DP; Göhmann E
ZFA (Stuttgart); 1978 May; 54(14):811-5. PubMed ID: 664826
[No Abstract] [Full Text] [Related]
19. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout.
Müller FO; Schall R; Groenewoud G; Hundt HK; van der Merwe JC; van Dyk M
Eur J Clin Pharmacol; 1993; 44(1):69-72. PubMed ID: 8436158
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid versus serum concentrations of 5-FU, allopurinol, and oxypurinol during treatment of metastatic brain cancer with 5-FU infusion, allopurinol, and radiation.
Hornbeck CL; Floyd RA; Byfield JE; Griffiths JC; Frankel S; Sharp TR
Cancer Treat Rep; 1982 Mar; 66(3):571-3. PubMed ID: 7060045
[No Abstract] [Full Text] [Related]
[Next] [New Search]
